GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I reiterate strong buy rating on GSK stock.